Compare Harley-Davidson Inc (HOG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs BIO-TECHNE Corp — how do they compare? Harley-Davidson Inc trades at $26.9 (market cap $2.78B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 4.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and BIO-TECHNE Corp for 64 Days on average.
| HOG | TECH | |
|---|---|---|
Market Cap | $2.78B | $11.36B |
Volume | 2,966,389 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $72.61 |
52-Week Low | $17.19 | $43.31 |
Typical Hold Time | 92 Days | 64 Days |
Enterprise Value | $3.20B | $11.39B |
Dividend Yield | 2.8% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.75, down 0.74% on the day, with a bullish technical signal from moving averages. Recent earnings show a mixed track record, with a Q2 2026 beat but misses in prior quarters. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, though net income remains positive. The stock is valued at a P/E of 14.86 and P/S of 0.72, below industry averages, while analyst sentiment is mixed with a $28.50 consensus target.
The outlook is cautious; while valuation appears attractive and technicals suggest near-term strength, declining revenue and margin pressures pose fundamental risks. Investor sentiment is divided, with institutional activity showing both accumulation and divestment. Key catalysts include execution of the 'Back to the Bricks' strategy, but tariff exposures and competitive threats remain headwinds.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
